The invention represents a hormonal replacement therapy to improve lacrimal gland function that has been impaired by menopause or estrogen-based oral contraceptive use.
Research indicates that there is an optimal level of the hormone prolactin.
Clinical studies show that most menopausal women have too much. The main idea of this study is to administer a medication that adjust prolactin levels, such as bromocriptine, and also administer an androgen, such as testosterone, at a level that may be individually adjusted. Together, this therapy maintains lacrimal gland function. Advantages Most dry eye patients are post-menopausal women. Oral contraceptive use, pregnancy, and lactaction are often associated wit contact-lens intolerance and believed to result from lacrimal insufficiency.